JP2016516043A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516043A5 JP2016516043A5 JP2016502444A JP2016502444A JP2016516043A5 JP 2016516043 A5 JP2016516043 A5 JP 2016516043A5 JP 2016502444 A JP2016502444 A JP 2016502444A JP 2016502444 A JP2016502444 A JP 2016502444A JP 2016516043 A5 JP2016516043 A5 JP 2016516043A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- compound
- optionally
- compound according
- branched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 34
- 239000001257 hydrogen Substances 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 7
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004450 alkenylene group Chemical group 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 5
- 125000004419 alkynylene group Chemical group 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 102000004157 Hydrolases Human genes 0.000 claims 1
- 108090000604 Hydrolases Proteins 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- -1 substituted Chemical class 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 0 *C(*)(*)N(*)*c1ccccc1 Chemical compound *C(*)(*)N(*)*c1ccccc1 0.000 description 16
- WHELBNUVILHIHT-UHFFFAOYSA-N Cc(cc1)ccc1-c1ncc[o]1 Chemical compound Cc(cc1)ccc1-c1ncc[o]1 WHELBNUVILHIHT-UHFFFAOYSA-N 0.000 description 8
- DXYYSGDWQCSKKO-UHFFFAOYSA-N Cc1nc2ccccc2[s]1 Chemical compound Cc1nc2ccccc2[s]1 DXYYSGDWQCSKKO-UHFFFAOYSA-N 0.000 description 3
- FKWHHXZNCQKLJG-UHFFFAOYSA-N CNCc(cccn1)c1Oc(cc1)ccc1C(O)=O Chemical compound CNCc(cccn1)c1Oc(cc1)ccc1C(O)=O FKWHHXZNCQKLJG-UHFFFAOYSA-N 0.000 description 2
- ALHUXMDEZNLFTA-UHFFFAOYSA-N Cc1nc2ccccc2nc1 Chemical compound Cc1nc2ccccc2nc1 ALHUXMDEZNLFTA-UHFFFAOYSA-N 0.000 description 2
- WGTUMQXQVLOHQE-UHFFFAOYSA-N CCCN(C)Cc1cccnc1Oc(cc1)ccc1C(OCC)=O Chemical compound CCCN(C)Cc1cccnc1Oc(cc1)ccc1C(OCC)=O WGTUMQXQVLOHQE-UHFFFAOYSA-N 0.000 description 1
- VGZHYZHNXNVWHH-UHFFFAOYSA-N CCCNCc(cc1)cnc1-[n]1c(C)c(C(O)=O)nc1 Chemical compound CCCNCc(cc1)cnc1-[n]1c(C)c(C(O)=O)nc1 VGZHYZHNXNVWHH-UHFFFAOYSA-N 0.000 description 1
- QEYUNVXPSOCBAG-UHFFFAOYSA-N CCNCc1cccnc1Oc1cc(C(O)=O)ccc1 Chemical compound CCNCc1cccnc1Oc1cc(C(O)=O)ccc1 QEYUNVXPSOCBAG-UHFFFAOYSA-N 0.000 description 1
- QMBLXRHXCGJOGU-UHFFFAOYSA-N CCc1ccc(CC(O)=O)cc1 Chemical compound CCc1ccc(CC(O)=O)cc1 QMBLXRHXCGJOGU-UHFFFAOYSA-N 0.000 description 1
- BHIQFQYCZIJUIG-UHFFFAOYSA-N CCc1ccc(CC(OC)=O)cc1 Chemical compound CCc1ccc(CC(OC)=O)cc1 BHIQFQYCZIJUIG-UHFFFAOYSA-N 0.000 description 1
- OLPWVSINLQYDIY-UHFFFAOYSA-N CN(C)Cc(cccn1)c1Oc(cc1)ccc1C(O)=O Chemical compound CN(C)Cc(cccn1)c1Oc(cc1)ccc1C(O)=O OLPWVSINLQYDIY-UHFFFAOYSA-N 0.000 description 1
- YMXQNJHJWAVADX-UHFFFAOYSA-N CN(C)Cc1ccc(N(CC2)CCC2C(O)=O)nc1 Chemical compound CN(C)Cc1ccc(N(CC2)CCC2C(O)=O)nc1 YMXQNJHJWAVADX-UHFFFAOYSA-N 0.000 description 1
- JBOVVZBMLVRDAP-UHFFFAOYSA-N CN(CCOC)Cc(cccc1)c1Oc1cccc(C(O)=O)c1 Chemical compound CN(CCOC)Cc(cccc1)c1Oc1cccc(C(O)=O)c1 JBOVVZBMLVRDAP-UHFFFAOYSA-N 0.000 description 1
- LJVIXOQEJPEWJW-UHFFFAOYSA-N CNCc(cc1)cnc1NCCC(O)=O Chemical compound CNCc(cc1)cnc1NCCC(O)=O LJVIXOQEJPEWJW-UHFFFAOYSA-N 0.000 description 1
- YCESUPDCBCISGX-UHFFFAOYSA-N CNCc(cccn1)c1Oc(ccc(C(O)=O)c1)c1OC Chemical compound CNCc(cccn1)c1Oc(ccc(C(O)=O)c1)c1OC YCESUPDCBCISGX-UHFFFAOYSA-N 0.000 description 1
- VYMYSBRLXXKRPA-UHFFFAOYSA-N CNCc1ccc(N(C)CC(O)=O)nc1 Chemical compound CNCc1ccc(N(C)CC(O)=O)nc1 VYMYSBRLXXKRPA-UHFFFAOYSA-N 0.000 description 1
- RPLYIPWVKQPFFL-UHFFFAOYSA-N CNCc1ccc(NCc(cc2)ccc2C(O)=O)nc1 Chemical compound CNCc1ccc(NCc(cc2)ccc2C(O)=O)nc1 RPLYIPWVKQPFFL-UHFFFAOYSA-N 0.000 description 1
- UDOMVKIVDINFMC-UHFFFAOYSA-N COC(c1ccc(CSC)cc1)=O Chemical compound COC(c1ccc(CSC)cc1)=O UDOMVKIVDINFMC-UHFFFAOYSA-N 0.000 description 1
- GHPODDMCSOYWNE-UHFFFAOYSA-N Cc(cc1)cc2c1OCO2 Chemical compound Cc(cc1)cc2c1OCO2 GHPODDMCSOYWNE-UHFFFAOYSA-N 0.000 description 1
- LNJMHEJAYSYZKK-UHFFFAOYSA-N Cc1ncccn1 Chemical compound Cc1ncccn1 LNJMHEJAYSYZKK-UHFFFAOYSA-N 0.000 description 1
- KCTZYAAHUYSVON-UHFFFAOYSA-N OC(c1ccc(CS)cc1)=O Chemical compound OC(c1ccc(CS)cc1)=O KCTZYAAHUYSVON-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361781168P | 2013-03-14 | 2013-03-14 | |
| US61/781,168 | 2013-03-14 | ||
| PCT/US2014/027449 WO2014152536A2 (en) | 2013-03-14 | 2014-03-14 | Inhibitors of leukotriene a4 hydrolase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016516043A JP2016516043A (ja) | 2016-06-02 |
| JP2016516043A5 true JP2016516043A5 (enExample) | 2017-04-13 |
| JP6562898B2 JP6562898B2 (ja) | 2019-08-21 |
Family
ID=51581719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502444A Active JP6562898B2 (ja) | 2013-03-14 | 2014-03-14 | ロイコトリエンａ４加水分解酵素の阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9822106B2 (enExample) |
| EP (1) | EP2968265A4 (enExample) |
| JP (1) | JP6562898B2 (enExample) |
| KR (1) | KR20150131211A (enExample) |
| AU (2) | AU2014239585B2 (enExample) |
| BR (1) | BR112015022227A2 (enExample) |
| CA (1) | CA2906086A1 (enExample) |
| MX (1) | MX2015011676A (enExample) |
| RU (1) | RU2690489C2 (enExample) |
| WO (1) | WO2014152536A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3205644A1 (en) | 2005-12-29 | 2017-08-16 | Celtaxsys Inc. | Diamine derivatives as inhibitors of leukotriene a4 hydrolase |
| AU2014249168B2 (en) | 2013-03-12 | 2018-07-12 | Celltaxis, Llc | Methods of inhibiting leukotriene A4 hydrolase |
| AU2014240042C1 (en) | 2013-03-14 | 2019-09-05 | Celltaxis, Llc | Inhibitors of leukotriene A4 hydrolase |
| MX2015011678A (es) | 2013-03-14 | 2016-07-08 | Celtaxsys Inc | Inhibidores de leucotrieno a4 hidrolasa. |
| US20170107216A1 (en) | 2015-10-19 | 2017-04-20 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MD3377488T2 (ro) | 2015-11-19 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
| ES2916874T3 (es) | 2015-12-17 | 2022-07-06 | Incyte Corp | Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1 |
| US12084472B2 (en) | 2015-12-18 | 2024-09-10 | Ardelyx, Inc. | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists |
| TWI773657B (zh) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物 |
| CA3009474A1 (en) | 2015-12-22 | 2017-06-29 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| EP3464279B1 (en) | 2016-05-26 | 2021-11-24 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| SG11201811414TA (en) | 2016-06-20 | 2019-01-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| US20180057486A1 (en) | 2016-08-29 | 2018-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018107158A1 (en) | 2016-12-09 | 2018-06-14 | Celtaxsys, Inc. | Monamine and monoamine derivatives as inhibitors of leukotriene a4 hydrolase |
| WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| US10308644B2 (en) | 2016-12-22 | 2019-06-04 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP4223369A1 (en) | 2016-12-22 | 2023-08-09 | Incyte Corporation | Immunomodulator compounds and methods of use |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| WO2019036024A1 (en) | 2017-08-17 | 2019-02-21 | Bristol-Myers Squibb Company | 2- (1,1'-BIPHENYL) -1H-BENZO [D] IMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS AGONISTS OF APELIN AND APJ FOR THE TREATMENT OF CARDIOVASCULAR DISEASES |
| US10925851B2 (en) | 2018-03-15 | 2021-02-23 | Regents Of The University Of Minnesota | Use of Tosedostat and related compounds as analgesics |
| SMT202300065T1 (it) | 2018-03-30 | 2023-05-12 | Incyte Corp | Composti eterociclici come immunomodulatori |
| CN112752756B (zh) | 2018-05-11 | 2024-06-25 | 因赛特公司 | 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物 |
| EP3801559B1 (en) | 2018-05-31 | 2025-01-01 | Celltaxis, LLC | Method of reducing pulmonary exacerbations in respiratory disease patients |
| TW202115059A (zh) | 2019-08-09 | 2021-04-16 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽 |
| JP7559059B2 (ja) | 2019-09-30 | 2024-10-01 | インサイト・コーポレイション | 免疫調節剤としてのピリド［３，２－ｄ］ピリミジン化合物 |
| EP4058461A1 (en) | 2019-11-11 | 2022-09-21 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| UY39377A (es) | 2020-08-14 | 2022-03-31 | Novartis Ag | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos |
| IL302590A (en) | 2020-11-06 | 2023-07-01 | Incyte Corp | Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL6815872A (enExample) * | 1967-11-22 | 1969-05-27 | ||
| US4582833A (en) | 1984-04-16 | 1986-04-15 | American Cyanamid Company | 2-(substituted-1-piperazinyl)[1,2,4]triazolo[1,5-a]pyrimidines |
| US4576943A (en) | 1984-10-09 | 1986-03-18 | American Cyanamid Company | Pyrazolo[1,5-a]pyrimidines |
| US5308852A (en) | 1992-06-29 | 1994-05-03 | Merck Frosst Canada, Inc. | Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis |
| US5631401A (en) * | 1994-02-09 | 1997-05-20 | Abbott Laboratories | Inhibitors of protein farnesyltransferase and squalene synthase |
| AU3577995A (en) * | 1994-10-04 | 1996-04-26 | Fujisawa Pharmaceutical Co., Ltd. | Urea derivatives and their use as acat-inhibitors |
| US6506876B1 (en) | 1994-10-11 | 2003-01-14 | G.D. Searle & Co. | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use |
| AU1952597A (en) | 1996-02-13 | 1997-09-02 | G.D. Searle & Co. | Combinations, having immunosuppressive effects, containing cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor |
| US5925654A (en) * | 1997-03-12 | 1999-07-20 | G.D. Searle & Co. | LTA4 , hydrolase inhibitors |
| US6309561B1 (en) | 1997-12-24 | 2001-10-30 | 3M Innovative Properties Company | Liquid crystal compounds having a chiral fluorinated terminal portion |
| US6380203B1 (en) | 1998-01-14 | 2002-04-30 | Merck & Co., Inc. | Angiogenesis inhibitors |
| US6054590A (en) * | 1998-03-25 | 2000-04-25 | Bristol-Myers Squibb Company | Imidazolone anorectic agents: II. phenyl derivatives |
| GB9815880D0 (en) | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
| GB9919776D0 (en) | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
| AR023659A1 (es) | 1998-09-18 | 2002-09-04 | Vertex Pharma | Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos |
| AU4537900A (en) * | 1999-05-17 | 2000-12-05 | Agouron Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
| US6699873B1 (en) | 1999-08-04 | 2004-03-02 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| US6924313B1 (en) * | 1999-09-23 | 2005-08-02 | Pfizer Inc. | Substituted tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
| AU2001234420A1 (en) * | 2000-02-03 | 2001-08-14 | Eli Lilly And Company | Potentiators of glutamate receptors |
| US6451798B2 (en) | 2000-02-22 | 2002-09-17 | Cv Therapeutics, Inc. | Substituted alkyl piperazine derivatives |
| US6552023B2 (en) | 2000-02-22 | 2003-04-22 | Cv Therapeutics, Inc. | Aralkyl substituted piperazine compounds |
| JP2001354657A (ja) | 2000-06-09 | 2001-12-25 | Sds Biotech:Kk | 置換ピペラジン誘導体及び農園芸用殺菌剤 |
| US6875483B2 (en) | 2000-07-06 | 2005-04-05 | Fuji Photo Film Co., Ltd. | Liquid crystal composition comprising liquid crystal molecules and alignment promoter |
| WO2002064211A1 (en) | 2001-02-09 | 2002-08-22 | Merck & Co., Inc. | Thrombin inhibitors |
| DE60229114D1 (en) | 2001-03-02 | 2008-11-13 | Axys Pharm Inc | Cathepsincystein-proteasehemmer |
| AUPR362001A0 (en) | 2001-03-08 | 2001-04-05 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| FR2826011B1 (fr) | 2001-06-14 | 2004-12-10 | Oreal | Nouveaux derives de la 7-oxo-dhea et utilisation cosmetique |
| SE0102616D0 (sv) | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| IL160845A0 (en) | 2001-09-14 | 2004-08-31 | Tularik Inc | Linked biaryl compounds |
| AU2002363236A1 (en) | 2001-10-30 | 2003-05-12 | Millennium Pharmaceuticals, Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
| AU2003234464B2 (en) * | 2002-05-03 | 2009-06-04 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| PT2208727E (pt) * | 2002-09-19 | 2012-10-11 | Lilly Co Eli | Éteres diarílicos como antagonista do receptor opióide |
| US7851486B2 (en) | 2002-10-17 | 2010-12-14 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
| AU2003290527A1 (en) | 2002-10-17 | 2004-05-04 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction |
| US20040198777A1 (en) * | 2002-12-20 | 2004-10-07 | Mitokor, Inc. | Ligands of adenine nucleotide translocase (ANT) and compositions and methods related thereto |
| JPWO2004089410A1 (ja) | 2003-04-03 | 2006-07-06 | 協和醗酵工業株式会社 | 神経因性疼痛の予防及び／または治療剤 |
| WO2004099164A1 (en) | 2003-05-02 | 2004-11-18 | Rigel Pharmaceuticals, Inc. | Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating hcv infection |
| JP2005008581A (ja) | 2003-06-20 | 2005-01-13 | Kissei Pharmaceut Co Ltd | 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| WO2005012296A1 (en) * | 2003-07-28 | 2005-02-10 | Janssen Pharmaceutica N.V. | Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators |
| CA2539276A1 (en) | 2003-09-17 | 2005-03-31 | Decode Genetics Ehf. | Methods of preventing or treating recurrence of myocardial infarction |
| US7932272B2 (en) * | 2003-09-30 | 2011-04-26 | Eisai R&D Management Co., Ltd. | Antifungal agent containing heterocyclic compound |
| DE10356579A1 (de) | 2003-12-04 | 2005-07-07 | Merck Patent Gmbh | Aminderivate |
| SE0303480D0 (sv) | 2003-12-19 | 2003-12-19 | Biovitrum Ab | Benzofuranes |
| ATE437880T1 (de) | 2004-02-04 | 2009-08-15 | Neurosearch As | Dimere azacyclische verbindungen und deren verwendung |
| WO2006033795A2 (en) | 2004-09-17 | 2006-03-30 | Wyeth | Substituted pyrazolo [1, 5-a] pyrimidines for inhibiting abnormal cell growth |
| WO2006105304A2 (en) * | 2005-03-31 | 2006-10-05 | Janssen Pharmaceutica N.V. | Phenyl and pyridyl lta4h modulators |
| JP2008540395A (ja) * | 2005-05-03 | 2008-11-20 | ファイザー・インク | アミドレソルシノール化合物 |
| CA2610671A1 (en) * | 2005-05-31 | 2006-12-07 | Astrazeneca Ab | Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders |
| GB0514018D0 (en) | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
| BRPI0616187A2 (pt) | 2005-09-21 | 2011-06-14 | Decode Genetics Ehf | composto, composiÇço farmacÊutica, e, uso de uma quantidade terapeuticamente eficaz de um composto |
| CN1947717B (zh) | 2005-10-14 | 2012-09-26 | 卓敏 | 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用 |
| DE102005049954A1 (de) | 2005-10-19 | 2007-05-31 | Sanofi-Aventis Deutschland Gmbh | Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen |
| EP3205644A1 (en) | 2005-12-29 | 2017-08-16 | Celtaxsys Inc. | Diamine derivatives as inhibitors of leukotriene a4 hydrolase |
| CN102633783A (zh) | 2006-02-10 | 2012-08-15 | 转化技术制药公司 | 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法 |
| EP1878730A1 (en) * | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same |
| EP2058309A4 (en) | 2006-08-04 | 2010-12-22 | Takeda Pharmaceutical | CONDENSED HETEROCYCLIC COMPOUND |
| BRPI0718059A2 (pt) | 2006-10-19 | 2013-11-05 | Holffmann La Roche Ag F | Aminometil-2-imidazóis com afinidade com os receptores amina-associado traço |
| ES2620818T3 (es) | 2006-12-14 | 2017-06-29 | Janssen Pharmaceutica N.V. | Procedimiento para la preparación de derivados de piperazinil y diazepanil benzamida |
| FR2911138B1 (fr) | 2007-01-05 | 2009-02-20 | Sanofi Aventis Sa | Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| FR2911140B1 (fr) | 2007-01-05 | 2009-02-20 | Sanofi Aventis Sa | Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| FR2911139A1 (fr) | 2007-01-05 | 2008-07-11 | Sanofi Aventis Sa | Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| RU2010103104A (ru) | 2007-07-02 | 2011-08-10 | Ф.Хоффманн-Ля Рош Аг (Ch) | Производные имидазола в качестве антагонистов рецептора ccr2 |
| CA2695331A1 (en) * | 2007-08-03 | 2009-02-12 | F. Hoffmann-La Roche Ag | Pyridinecarboxamide and benzamide derivatives as taar1 ligands |
| US7902181B2 (en) | 2007-12-12 | 2011-03-08 | Astrazeneca Ab | Compounds 010 |
| FR2928070A1 (fr) * | 2008-02-27 | 2009-09-04 | Sumitomo Chemical Co | Composition agricole, utilisation d'un compose pour sa production et procede pour matriser ou prevenir les maladies des plantes. |
| US20100029657A1 (en) | 2008-02-29 | 2010-02-04 | Wyeth | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof |
| PT2268646E (pt) * | 2008-04-11 | 2013-12-10 | Janssen Pharmaceutica Nv | Aminas de tiazolopiridina-2-iloxi-fenil e de tiazolopirazina-2-iloxi-fenilo como moduladores da hidrolase de leucotrieno a4 |
| EP2110374A1 (en) | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
| WO2010011912A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Trpv4 antagonists |
| CN102030700B (zh) * | 2009-09-30 | 2016-06-01 | 中国医学科学院药物研究所 | 苯甲酰胺基羧酸类化合物及其制法和药物用途 |
| AU2010328419A1 (en) | 2009-12-07 | 2012-06-21 | Targacept, Inc. | 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands |
| JP2013047189A (ja) * | 2009-12-25 | 2013-03-07 | Kyorin Pharmaceutical Co Ltd | 新規パラバン酸誘導体及びそれらを有効成分とする医薬 |
| HUE052110T2 (hu) | 2010-07-29 | 2021-04-28 | Rigel Pharmaceuticals Inc | AMPK-t aktiváló heterociklusos vegyületek és alkalmazásuk |
| AP3339A (en) * | 2011-03-14 | 2015-07-31 | Boehringer Ingelheim Int | Benzodioxane inhibitors of leukotriene production |
| WO2012125832A2 (en) * | 2011-03-15 | 2012-09-20 | Rib-X Pharmaceuticals, Inc. | Antimicrobial agents |
| EP2714661B1 (en) * | 2011-05-23 | 2015-09-30 | Janssen Pharmaceutica, N.V. | Picolinamido - propanoic acid derivatives useful as glucagon receptor antagonists |
| US9006235B2 (en) | 2012-03-06 | 2015-04-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| AU2014249168B2 (en) | 2013-03-12 | 2018-07-12 | Celltaxis, Llc | Methods of inhibiting leukotriene A4 hydrolase |
| AU2014240042C1 (en) | 2013-03-14 | 2019-09-05 | Celltaxis, Llc | Inhibitors of leukotriene A4 hydrolase |
| MX2015011678A (es) | 2013-03-14 | 2016-07-08 | Celtaxsys Inc | Inhibidores de leucotrieno a4 hidrolasa. |
-
2014
- 2014-03-14 EP EP14769620.7A patent/EP2968265A4/en not_active Withdrawn
- 2014-03-14 WO PCT/US2014/027449 patent/WO2014152536A2/en not_active Ceased
- 2014-03-14 AU AU2014239585A patent/AU2014239585B2/en not_active Ceased
- 2014-03-14 MX MX2015011676A patent/MX2015011676A/es unknown
- 2014-03-14 KR KR1020157028770A patent/KR20150131211A/ko not_active Ceased
- 2014-03-14 JP JP2016502444A patent/JP6562898B2/ja active Active
- 2014-03-14 RU RU2015137977A patent/RU2690489C2/ru not_active IP Right Cessation
- 2014-03-14 CA CA2906086A patent/CA2906086A1/en not_active Abandoned
- 2014-03-14 BR BR112015022227A patent/BR112015022227A2/pt not_active Application Discontinuation
-
2015
- 2015-09-10 US US14/849,829 patent/US9822106B2/en not_active Expired - Fee Related
-
2017
- 2017-11-02 US US15/801,494 patent/US20180118735A1/en not_active Abandoned
-
2019
- 2019-07-02 AU AU2019204753A patent/AU2019204753A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513696A5 (enExample) | ||
| JP2016513681A5 (enExample) | ||
| JP2016506962A5 (enExample) | ||
| JP2015522650A5 (enExample) | ||
| JP2014503574A5 (enExample) | ||
| JP2015520769A5 (enExample) | ||
| JP2016506961A5 (enExample) | ||
| JP2019501125A5 (enExample) | ||
| JP2014506907A5 (enExample) | ||
| JP2011513305A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| RU2015146957A (ru) | Производные доластатина 10 и ауристатинов | |
| JP2016526576A5 (enExample) | ||
| JP2017509586A5 (enExample) | ||
| JP2014506599A5 (enExample) | ||
| JP2013512903A5 (enExample) | ||
| JP2015500887A5 (enExample) | ||
| JP2017526677A5 (enExample) | ||
| MX336505B (es) | Metodos y composiciones para reducir la grasa y los adipocitos del cuerpo. | |
| JP2014508804A5 (enExample) | ||
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| JP2018527295A5 (enExample) | ||
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| JP2013523814A5 (enExample) |